Latest From AxoGen Inc.
The study will be expanded by 50 patients, for a total of 220 subjects, based on the recommendation of a statistician who reviewed an interim analysis. RECON is intended to support a Biologic License Application for Avance, a processed human nerve allograft for bridging severed peripheral nerves.
Starts & Stops: Boston Scientific Launches New Lotus TAVR Trial, Medtronic Starts Study Of SynchroMed II Pain Pump
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 7 through Jan. 27, including announcements from Medtronic, QT Vascular, Boston Scientific, and Shockwave.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance or Financing. This month’s column covers deals announced in November 2017.
- Implantable Devices
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- AxoGen Inc.
- Senior Management
Karen Zaderej, Chmn., Pres. & CEO
Peter J Mariani, CFO
Gregory G Freitag, General Counsel, SVP & Dir., Bus. Dev.
Jon Gingrich, Chief Commercial Officer
Shawn McCarrey, SVP, Sales
Kevin Leach, VP, Mktg.
Mike Donovan, VP, Operations
- Contact Info
Phone: (386) 462-6800
13859 Progress Blvd.
Alachua, FL 32615
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.